<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[15, 22] chemotherapy-induced painful peripheral neuropathy:<br>[91, 113] 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011.<br>[150, 197] patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment.<br></td>
<td width=33%>
[13, 22] patients with chemotherapy-induced painful peripheral neuropathy:<br>[91, 113] 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011.<br>[147, 198] Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment.
<br></td>
<td width=33%>
[13, 22] patients with chemotherapy-induced painful peripheral neuropathy:<br>[80, 85] 8 National Cancer Institute (<br>[86, 113] cooperative research networks that enrolled 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011.<br>[147, 198] Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment.
<br>[255, 262] chemotherapy-induced peripheral neuropathic pain.<br>[403, 412] patients with painful chemotherapy-induced peripheral neuropathy,<br></td>
</tr>
